.25 mg semaglutide in syringe Medicare to cover GLP-1 treatments for weight loss Weight-loss injection poisonings nearly double

10.2147/IJN.S213883 53 JelovacN.SikiricP.RucmanR.PetekM.MarovicA.PerovicD.et al (1999)

Further research, including prospective studies and registry data, is needed to better understand the safety profile, potential benefits, and risks of GLP-1 therapy in individuals with Crohn's disease

The STEP 5 data suggests that ongoing administration is necessary to maintain results, as participants who discontinued semaglutide in the STEP 1 extension study regained approximately two-thirds of the weight they had lost within one year of stopping

In conclusion, TMAO levels hold promise as a potential biomarker for predicting CKD progression and the risk of associated complications